Literature DB >> 31714952

Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis.

Marco Basset1,2, Irene Defrancesco1, Paolo Milani1,2, Mario Nuvolone1,2, Sara Rattotti3, Andrea Foli1,2, Silvia Mangiacavalli3, Marzia Varettoni3, Pietro Benvenuti3, Claudio Salvatore Cartia3, Marco Paulli1,4, Giampaolo Merlini1,2, Luca Arcaini1,3, Giovanni Palladini1,2.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 31714952     DOI： 10.1182/blood.2019002762

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Localized Peritumoral AL Amyloidosis Associated With Mantle Cell Lymphoma With Plasmacytic Differentiation.

Authors:  Mariko Yabe; Neval Ozkaya; Daphne de Jong; Umut Aypar; M Stella Ritorto; Ellis Barbé; Iris H C Miedema; Filiz Sen; Jessica R Chapman; Heather J Landau; Ahmet Dogan
Journal:  Am J Surg Pathol       Date:  2021-07-01       Impact factor: 6.298

2.  Immunoglobulin Light Chain (AL) Amyloidosis Preceding Marginal Zone Lymphoma: A Case Report.

Authors:  Krishna Doshi; Jacob Bitran; Brian Adley; Nahren Asado
Journal:  Cureus       Date:  2022-07-02

3.  Extracellular Volume Fraction Based on Cardiac Magnetic Resonance T1 Mapping: An Effective Way to Evaluate Cardiac Injury Caused by Cardiac Amyloidosis in Patients with Multiple Myeloma.

Authors:  Minghui Liu; Liang Shao; Zhaoxia Yang; Qian Wang; Balu Wu; Xiaoyan Liu; Yalan Yu; Tingting Huang; Meixing Wang; Yong He; Guohong Liu; Fuling Zhou
Journal:  J Immunol Res       Date:  2022-08-13       Impact factor: 4.493

Review 4.  Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.

Authors:  Giovanni Palladini; Paolo Milani; Fabio Malavasi; Giampaolo Merlini
Journal:  Cells       Date:  2021-03-04       Impact factor: 6.600

5.  Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study.

Authors:  Andrew Staron; Luke Zheng; Gheorghe Doros; Lawreen H Connors; Lisa M Mendelson; Tracy Joshi; Vaishali Sanchorawala
Journal:  Blood Cancer J       Date:  2021-08-04       Impact factor: 11.037
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.